Biomarin Pharmaceutical (BMRN) Current Deferred Tax Assets (2010 - 2015)

Biomarin Pharmaceutical (BMRN) has 6 years of Current Deferred Tax Assets data on file, last reported at $30.9 million in Q3 2015.

• Quarterly Current Deferred Tax Assets rose 5.94% year-over-year to $30.9 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $30.9 million (up 5.94% YoY) and the FY2014 annual result came in at $31.2 million, up 2.09% from the prior year.
• Current Deferred Tax Assets eased to $30.9 million in Q3 2015, from $31.2 million in the prior quarter.
• In the past five years, Current Deferred Tax Assets ranged from a high of $32.4 million in Q4 2012 to a low of $16.7 million in Q2 2011.
• A 5-year average of $27.2 million and a median of $30.0 million in 2013 frame the typical range for Current Deferred Tax Assets.
• Annual changes were most pronounced in 2012 — Current Deferred Tax Assets soared 53.24% — and 2014, when it fell 9.58%.
• Tracing BMRN's Current Deferred Tax Assets over 5 years: stood at $21.1 million in 2011, then soared by 53.24% to $32.4 million in 2012, then declined by 5.55% to $30.6 million in 2013, then rose by 2.09% to $31.2 million in 2014, then dropped by 1.03% to $30.9 million in 2015.
• The last three Current Deferred Tax Assets figures came in at $30.9 million (Q3 2015), $31.2 million (Q2 2015), and $31.2 million (Q1 2015), per Business Quant data.